Metabolism Flashcards
Olezarsen
Reduces hepatic synthesis of apolipoprotein C-III thereby decreasing triglycerides
Fatty liver is now called
metabolic-associated fatty liver,
Insulin resistance causes:
- Fatty acid storage in hepatocytes
- De novo synthesis of fatty acids
- Lipolysis is inhibited
- adiponectin is inhibited (antilipogenesis)
- Increase systemic inflammation and oxidative stress
Adipose tissue releases inflammatory markers
- Tumor necrosis factor alpha
- iL-1
- iL-6
- CRP
Inflammatory cytokines induce
- Fibrinogen
- Factor VIII
- plasminogen activator inhibitor-1
Oxidative stress induces
Platelet aggregation
Nomenclatura for fatty liver 2023
meta- bolic dysfunction-associated steatotic liver disease’ (MASLD)
MASH (metabolic dysfunction-associated steatohepatitis.
Tirzepatide (reduces MASH, fibrosis)
Agonistglucose dependent insulinotrope polypeptide and glucagon like peptide-1receptor agonist.(7/25/24 vol. 391 #4 p299
MASH NEJM 7/25/24 Vol391#4 p311-319
Survodutide
Dual agonism GLP1
MASH NEJM 2024 ;390: 497-509
Resmetirom
Evolucamab
Anti lipid
Labs to determine type 1 or type 2 DM
Type 1 or type 2
GAD 65
IA2
ICA
ZINC TRANSPORTER
Intestinal congestion
Gut bacterial translocation in intestinal congestion
Intestinal congestion
Gut bacterial translocation in intestinal congestion
ANION GAP METABOLIC ACIDOSIS
GOLD MARK
G glycols (ethylene glycol) check glycol
O 5-oxoproline level (Acetaminophen long term basis
L lactate type A no oxygen//typeB metabolic- metformin
L lactate D short bowel syndrome
Cont GOLD MARK
Methanol
Aspirin
Renal failure
Ketoacidosis starvation, alcohol, diabetes (euglycemic DKA due to SGLT2 inhibition)
MASLD
Metabolic dysfunction associated steatotic liver disease
MASLD
Metabolic dysfunction associated steatotic liver disease
Resmetirom thyroid hormone receptor beta selective agonist for treatment of MASH w/ stage 2 or 3 fibrosis.
